Holen Sie sich die Stockscreener-App
3.20
57.64%
1.17
Handel nachbörslich:
2.90
-0.30
-9.38%
Schlusskurs vom Vortag:
$2.03
Offen:
$2.08
24-Stunden-Volumen:
43.56M
Relative Volume:
14.21
Marktkapitalisierung:
$4.26M
Einnahmen:
$9.81M
Nettoeinkommen (Verlust:
$-26.16M
KGV:
-0.0825
EPS:
-38.77
Netto-Cashflow:
$-17.45M
1W Leistung:
+24.03%
1M Leistung:
+34.45%
6M Leistung:
-94.96%
1J Leistung:
-98.73%
1-Tages-Spanne:
$2.04
$4.05
1-Wochen-Bereich:
$1.87
$4.05
52-Wochen-Spanne:
$1.87
$303.25
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Firmenname
Reshape Lifesciences Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Vergleichen Sie RSLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
3.20 | 4.84M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 4.14B | 577.90M | 6.96 |
Reshape Lifesciences Inc Aktie (RSLS) Neueste Nachrichten
ReShape Lifesciences' Merger With Vyome Therapeutics Receives Nasdaq Approval for Listing - MarketScreener
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - Yahoo Finance
Recovery Setup Building in ReShape Lifesciences Inc. Experts SayJuly 2025 Opening Moves & Verified Trade Idea Suggestions - 선데이타임즈
Vyome Therapeutics Sets Board To Lead Reshape Lifesciences Post-Close; New Entity To Trade As Vyome Holdings Under Ticker Symbol HIND - 富途牛牛
MIT AI Experts Take Control: Inside Vyome's Complete Board Overhaul Before Major NASDAQ Debut - Stock Titan
How ReShape Lifesciences Inc. stock performs during market volatilityFree Portfolio Optimization Guide - newsyoung.net
ReShape Lifesciences shareholders approve merger with Vyome Therapeutics - MSN
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Lifesciences Approves Asset Sale and Merger - TipRanks
ReShape Lifesciences RSLS 2025Q2 Earnings Preview Upside Potential on Strategic Reshape Initiatives - AInvest
ReShape Lifesciences Shareholders Approve Merger with Vyome Therapeutics, Ticker Symbol to Change to HIND - AInvest
ReShape announces shareholder approval of Vyome merger - TipRanks
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - Business Wire
How does ReShape Lifesciences Inc. generate profit in a changing economyAccess high-quality stock research instantly - Jammu Links News
What are the latest earnings results for ReShape Lifesciences Inc.Navigate the market with precision tools - Jammu Links News
What are analysts’ price targets for ReShape Lifesciences Inc. in the next 12 monthsRapid-fire capital growth - Jammu Links News
Is it the right time to buy ReShape Lifesciences Inc. stockGet real-time alerts on top-performing stocks - Jammu Links News
How strong is ReShape Lifesciences Inc. company’s balance sheetExceptional trading results - Jammu Links News
Is ReShape Lifesciences Inc. a growth stock or a value stockCapitalize on momentum-driven opportunities - Jammu Links News
What is the dividend policy of ReShape Lifesciences Inc. stockUnlock expert trading strategies for growth - Jammu Links News
What are the technical indicators suggesting about ReShape Lifesciences Inc.Accelerated profit realization - Jammu Links News
What are ReShape Lifesciences Inc. company’s key revenue driversSpectacular growth rates - Jammu Links News
When is ReShape Lifesciences Inc. stock expected to show significant growthBuild a winning investment strategy today - Jammu Links News
What institutional investors are buying ReShape Lifesciences Inc. stockAchieve breakthrough financial results - Jammu Links News
Why ReShape Lifesciences Inc. stock attracts strong analyst attentionLow Risk Picks for Daily Trading Released - beatles.ru
ReShape Lifesciences Inc. Pullback Analyzed — Is It Time to ExitAI Forecast for Trending Stocks Indicates Upside - metal.it
ReShape Lifesciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutWatchlist for Smart Swing Trading Updated - metal.it
Published on: 2025-07-29 19:35:19 - metal.it
Options Data Show Bullish Bias in ReShape Lifesciences Inc.Pattern Alert With ROI Driven Strategy Shared - metal.it
ReShape Lifesciences Inc. Inches Toward Key Resistance — Will It BreakReal Trader Watchlist of Hot Stocks Released - metal.it
ReShape Lifesciences Holds Special Stockholder Meeting - TipRanks
ReShape Lifesciences Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - Autocar Professional
What drives ReShape Lifesciences Inc. stock priceTremendous growth potential - PrintWeekIndia
What analysts say about ReShape Lifesciences Inc. stockPhenomenal capital appreciation - Autocar Professional
Will ReShape Lifesciences Inc. stock split in the near futureOverwhelming profit margins - jammulinksnews.com
ReShape Lifesciences Holds Special Stockholder Meeting to Discuss Merger and Asset Sale. - AInvest
ReShape Lifesciences Announces Partial Adjournment of Stockholder Meeting for Asset Sale and Charter Amendment Proposals - Nasdaq
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders - GlobeNewswire
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
Is ReShape Lifesciences Inc. a good long term investmentHigh-profit stock alerts - jammulinksnews.com
Finanzdaten der Reshape Lifesciences Inc-Aktie (RSLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):